However, in people with mild cognitive impairment, the presence of depressive symptoms was tied to a lower likelihood of amyloid pathology (OR 0.73, 95% CI 0.61-0.89, P =0.001), Oomens and colleagues ...

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy ...

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).

Why: Depression is common in late life, effecting nearly five million of the 31 million Americans aged 65 and older. Both major and minor depression are reported in 13% of community dwelling older ...

On Tuesday, the FDA approved Johnson & Johnson’s (NYSE:JNJ) supplemental New Drug Application for Spravato (esketamine) CIII ...

The FDA approves Johnson & Johnson's sNDA for Spravato as a monotherapy for adults with treatment-resistant depression.

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

Stressed-out teenagers appear to be dragging down the U.S. economy, a new study says. Teenagers suffering from anxiety or ...

Johnson & Johnson has received FDA approval for Spravato nasal spray as the first and only monotherapy for adults with treatment-resistant depression.

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...